stella
Crohn's DiseaseJune 2021Summary reviewed August 2026

An Under-the-Skin Shot Worked as Well as an IV for Crohn's and Colitis

Patients with inflammatory bowel disease got the same relief from a shot they could take at home every two weeks as from an IV infusion in the clinic every eight weeks. Both groups had similar remission rates and side effects. The at-home option could mean fewer hospital visits.

What the trial was testing

The trial enrolled 181 patients with crohn's disease. The study was sponsored by Celltrion and tracked outcomes across the full group of patients who matched the trial's eligibility profile.

It was an early-stage trial — researchers are still confirming safety and getting an early look at how well the treatment works. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.

What the results showed

The under-the-skin shot kept drug levels just as high as the IV infusion.

Gastroenterology · 2021 · NCT02883452

These findings — that the shot kept drug levels in the blood even higher than the IV — were published in the Gastroenterology and represent the headline result of the study.

Researchers tracked outcomes across 181 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.

What this means for patients

For patients with crohn's disease, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.

What you can do now

This study tested a more convenient way to get infliximab, a drug already FDA-approved for Crohn's and ulcerative colitis. If your doctor prescribes this treatment, you might be able to switch from clinic infusions to shots you give yourself at home. Ask your gastroenterologist if this option is right for you.

Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.

Open crohn's disease trials

RecruitingObservational study

Predictors of Prognosis in IBD Patients

A study of clinical characteristics and potential prognostic factors in inflammatory bowel disease

Seongnam-si, Gyeonggi-do, South Korea
RecruitingInterventional study

KONO-S Anastomosis Compared to Conventional Ileocolonic Anastomosis to Reduce Recurrence in Crohn's Disease

Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) currently affecting one person in a thousand in France. It can lead to numerous digestive complications such as fistulas, abscesses or stenosis. Despite numerous therapeutic advances, the rate of patients requiring surgery remains very high, with approximately 50% requiring at least one surgical intervention at 10 years after disease diagnosis. However, surgical treatment is not curative, the postoperative recurrence rate being very high, from 65 to-90% endoscopic recurrence at 1 year. The ileocolonic anastomosis is the main site of postoperative recurrence currently defined by a Rutgeerts score (≥i2) 6 months after surgery. In 2003, Kono et al. described a new operative technique that could reduce the rate of post-operative recurrence: a termino-terminal ileocolonic anastomosis, anti-mesenteric, with a supporting column to prevent distortion and anastomotic stenosis (Kono-S anastomosis). The study showed no decrease in endoscopic recurrence rate at 1 year (83% vs 79%), but a significant decrease in surgical recurrence rate at 5 years (15% vs 0%). Recently, a randomized Italian monocenter study showed a significant decrease in endoscopic recurrence rate at 6 and 18 months (22.2% versus 62.8% and 25% versus 67.4%), as well as a decrease in clinical recurrence. The limitations of this study are its monocentric nature and the lack of centralization of the endoscopic analysis to assess the primary endpoint. This surgical technique has been performed in some centers for ileocolonic Crohn's surgery since 2020. Nevertheless, the level of evidence remains too low to establish practice recommendations. The KOALA study will be the first prospective, multicenter, randomized study comparing KONO-S anastomosis and conventional anastomosis for ileocolonicresection of Crohn's disease, with blinded and centralized evaluation of recurrence.

Besançon, France +14 more